Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-15

Study Completion Date

2021-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety and efficacy of H.P. Acthar gel for treating the cutaneous manifestations in patients with refractory classic dermatomyositis, juvenile dermatomyositis, and amyopathic dermatomyositis. Our hypothesis is that H.P. Acthar gel will be both safe and effective for such patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CNS Sarcoidosis and Acthar Gel

NCT02298491

CNS Sarcoidosis

COMPLETED PHASE4

Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

NCT00005571

Dermatomyositis

COMPLETED PHASE2

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177

Ocular Sarcoidosis Panuveitis Anterior Uveitis

COMPLETED NA

Abatacept in Juvenile Dermatomyositis

NCT02594735

Dermatomyositis

COMPLETED PHASE4

Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis

NCT07012057

Myositis Dermatomyositis

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adult and juvenile dermatomyositis (DM) are systemic immune-mediated inflammatory diseases most commonly affecting the skin and musculoskeletal system. Amyopathic dermatomyositis is a subtype of dermatomyositis that affects only the skin and lacks the characteristic muscle involvement. Treatment of these conditions, in particular the cutaneous manifestations, is challenging and currently no universally effective single treatment exists. Many patients have cutaneous manifestations that are refractory to numerous medications.

H.P. Acthar gel (adrenocorticotropic hormone gel) received FDA approval for treatment of a variety of diseases, including dermatomyositis, in 1952. Despite this there is a paucity of clinical data concerning the efficacy of H.P. Acthar gel for treating dermatomyositis. Recently a small, retrospective case series describing significant improvement in both cutaneous and musculoskeletal symptoms in 5 patients with refractory dermatomyositis treated with H.P. Acthar gel was reported and has resulted in renewed interest in use of this medication in dermatomyositis patient (reference below). The proposed efficacy of H.P. Acthar gel has been attributed to its unique ability to induce production of endogenous cortisol, corticosterone, aldosterone, and to bind melanocortin receptors on lymphocytes and other cells to modulate immunologic responses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatomyositis Juvenile Dermatomyositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

H.P Acthar Gel

80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks

Group Type EXPERIMENTAL

H.P. Acthar Gel

Intervention Type DRUG

80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H.P. Acthar Gel

80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acthar Gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be 18 years of age or older with refractory cutaneous symptoms related to either classic dermatomyositis (CD), juvenile dermatomyositis (JD), or amyopathic dermatomyositis(AD). Diagnosis will be based on either Bohan and Peter criteria (CD and JD) or Sontheimer's criteria (AD)
* Must have had a skin biopsy with histologic features consistent with dermatomyositis and current cutaneous manifestations consistent with dermatomyositis.
* Although not mandatory, patients with evidence of current or previous active myositis will be eligible for enrollment. Patients will be considered to have refractory disease if cutaneous manifestations exist despite treatment with steroids and at least one steroid-sparing systemic treatment commonly found to be useful in patients with dermatomyositis. These may include azathioprine, cyclosporine, mycophenolate mofetil, IVIG, methotrexate, cyclophosphamide, chlorambucil, sirolimus, adalimumab, infliximab and rituximab.
* Use of topical medications and sunscreen currently and in past will be noted but not weighed for assessment of refractory cutaneous disease.

Exclusion Criteria

* Patients with dermatomyositis who have minimal-to-no active cutaneous features (focal involvement with less than 1% total body surface area involved or minimal modified CDASI activity score).
* Patients whose cutaneous findings are not consistent with dermatomyositis and/or have previous biopsy results suggestive of an alternative diagnosis
* Patients with inflammatory myositis other than dermatomyositis, such as polymyositis or inclusion body myositis.
* Patients with malignancy-associated dermatomyositis
* Patients with clear features of an overlap myositis
* Patients younger than 18 years old
* Patients with acutely active or chronic infections.
* Patients with uncontrolled diabetes, hypertension, cardiovascular, hepatic, or renal disease
* Pregnant or lactating females.
* Patients with any medical condition that is felt by the primary investigator to place the patient at unreasonable risk for adverse effects during treatment with H.P. Acthar.
* Hypersensitivity to H.P. Acthar, any of its components (allergy to pig-derived proteins)
* Patients with osteoporosis
* Patients who have had surgery within 8 weeks of screening
* Patients with a history of or current gastric ulcers
* Patients taking daily doses of systemic corticosteroids greater than the equivalent of 40mg prednisone.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No